| Q45286739 | A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections |
| Q52016990 | A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. |
| Q35649774 | A prospective randomized trial of imipenem-cilastatin versus clindamycin/tobramycin in the treatment of intra-abdominal and pelvic infections |
| Q24246927 | Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults |
| Q44012058 | Antibiotic treatment for surgical peritonitis |
| Q41324755 | Antimicrobial therapy for intraabdominal infection |
| Q53993909 | Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. |
| Q24599288 | Canadian practice guidelines for surgical intra-abdominal infections |
| Q28299749 | Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use |
| Q72554827 | Clinical significance of anaerobic bacteremias in a general hospital. A prospective study from 1988 to 1992 |
| Q40879325 | Combination antibiotic therapy in the management of intra-abdominal infection. |
| Q36156077 | Combination therapy for treatment of infections with gram-negative bacteria |
| Q57773615 | Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections |
| Q70555080 | Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration |
| Q43780021 | Comparison of the Efficacy of Three Different Treatments with Imipenem Versus the Classical Clindamycin Plus Tobramycin in Experimental Peritonitis |
| Q74822958 | Cost analysis of imipenem-cilastatin versus clindamycin with tobramycin in the treatment of acute intra-abdominal infection |
| Q73419051 | Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections |
| Q35212734 | Current antimicrobial therapy of anaerobic infections |
| Q35650100 | Current indications for the use of clindamycin: A critical review |
| Q35534217 | Current perspectives on antibiotic use in the treatment of surgical infections |
| Q35138302 | Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group |
| Q70575282 | Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections |
| Q40888434 | Empiric antibiotic therapy of abdominal sepsis and serious perioperative infections |
| Q72416841 | Empirical antibiotic treatment of sepsis in non-neutropenic patients: single agent or combination therapy? |
| Q34026343 | Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations |
| Q35057515 | Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. |
| Q68146821 | Evaluation of Definitions for Sepsis |
| Q40558538 | Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. |
| Q28260317 | Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects |
| Q33560379 | Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections |
| Q40675256 | Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections |
| Q41724357 | Inappropriate hospital care and severity of illness: results from a nationwide study |
| Q43767713 | Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents |
| Q40490625 | Intra-abdominal infections in children. Pathogenesis, diagnosis and management |
| Q36719679 | Intra-abdominal infections: considerations for the use of the carbapenems |
| Q72242859 | Intra-abdominal sepsis |
| Q41324816 | Let us shorten antibiotic prophylaxis and therapy in surgery |
| Q33840068 | Management of complicated intra-abdominal infections |
| Q41014287 | Management of secondary peritonitis |
| Q53933241 | Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections. |
| Q53979811 | Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections. |
| Q34059386 | Meropenem: an updated review of its use in the management of intra-abdominal infections |
| Q46350390 | Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections |
| Q73304019 | Microbiology and management of intra‐abdominal infections in children |
| Q33603331 | Monobactams and carbapenems for treatment of intraabdominal infections |
| Q33980144 | Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group |
| Q33840063 | New advances in the use of antimicrobial agents in surgery: intra-abdominal infections |
| Q34028070 | New developments and concepts in antimicrobial therapy for intra-abdominal infections |
| Q38972381 | Optimal Treatment for Complicated Intra-abdominal Infections in the Era of Antibiotic Resistance: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Therapy With Metronidazole |
| Q71970381 | Pathogenesis and Prevention of Early Pancreatic Infection in Experimental Acute Necrotizing Pancreatitis |
| Q41014098 | Pharmacodynamics of antimicrobial therapy in surgery. |
| Q36758337 | Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections |
| Q54200566 | Piperacillin/tazobactam in the treatment of polymicrobial infections. |
| Q36162369 | Prevention of infectious complications in severe acute pancreatitis with systemic antibiotics: where are we now? |
| Q77491776 | Primary and secondary peritonitis: an update |
| Q77488468 | Prognostic scores and design of clinical studies |
| Q33701687 | Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis |
| Q73924214 | Prospective randomized trials affect the outcomes of intraabdominal infection |
| Q52241129 | Quantifying risk and assessing outcome in cardiac surgery. |
| Q36847059 | Quantifying risk and benchmarking performance in the adult intensive care unit |
| Q45162945 | Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection |
| Q79955480 | Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections |
| Q34581503 | Recent developments in carbapenems |
| Q28345630 | Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections |
| Q44625981 | Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group |
| Q44104580 | Risk factors for anastomotic leakage and favorable antimicrobial treatment as empirical therapy for intra-abdominal infection in patients undergoing colorectal surgery |
| Q43934218 | Severity and predicted outcome of postoperative Pseudomonas aeruginosa infections |
| Q35139440 | Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates |
| Q40720110 | The case for using objective scoring systems to predict intensive care unit outcome. |
| Q42218823 | The risk of seizures among the carbapenems: a meta-analysis. |
| Q72811542 | The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam |
| Q40759160 | Therapeutic options in peritonitis. |
| Q34476089 | Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations |
| Q41683130 | Traumatic and nontraumatic perforation of hollow viscera |
| Q33303029 | Treatment of the intraabdominal abscesses through percutaneous ultrasound-guided drainage in oncological patients: Clinical and microbiological data |
| Q77959593 | Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group |
| Q41269002 | Utilization of acute inpatient services for alcohol detoxification |
| Q74339709 | [Community-acquired peritonitis. Therapeutic follow-up in the case of secondary aggravation: the importance of microbiological results and medical imaging] |